Meet Our Executive Team

oncology-analytics-rick-deanRick Dean
Chief Executive Officer
Rick Dean serves as CEO of Oncology Analytics. Mr. Dean brings more than two decades of experience to Oncology Analytics, including successfully leading and growing innovative healthcare companies through various stages of maturation. Mr. Dean joined Oncology Analytics from Optum, the healthcare services arm of UnitedHealth Group. At Optum, Mr. Dean was a founding member of Optum Ventures, a venture capital fund focused on digital health innovation. Prior to Optum Ventures, he led global sales and growth for Optum Analytics.
Mr. Dean joined Optum after the acquisition of Humedica, a transformative population health and analytics company, where he was the company’s Chief Growth Officer. Prior to Humedica, Mr. Dean was senior vice president of North American sales for Sentillion, a highly successful venture backed healthcare company that was acquired by Microsoft in 2010. Mr. Dean is a past Board member of AMGA Analytics, the informatics subsidiary of the American Medical Group Association.

Mr. Dean earned a Bachelor of Science degree in Finance from the University of North Carolina.

oncology-analytics-marc-fishmanMarc Fishman, MD
Executive Chairman
Dr. Fishman founded Oncology Analytics (OA) in 2008. OA has grown rapidly, currently providing comprehensive oncology benefits management for members of health plans diagnosed with cancer. Through clinical research, patented technology and patient focused customer services, OA ensures treating oncologists have the information they need to deliver the most efficacious, least toxic and most affordable chemotherapy treatments available to their patients. Inc. Magazine’s 2013 Inc 500|5000 list named OA in the top 20 of the fastest growing private healthcare companies in the United States.
Dr. Fishman developed his perspective on health care management and funding mechanisms through a wide variety of clinical experiences, including work in Kenya, New Zealand, Canada and Australia in addition to the United States. Seeing the differences in care delivery systems, policy priorities and financing methods has provided him with unique insights into opportunities for improvement in the United States, which he is bringing to the market through OA. His combination of more than 20 years of clinical treatment experience and exposure to multi-national health systems have reinforced his commitment to value-based care for providing quality cancer treatment to all those who need it in the face of the enormous costs, waste and poorly aligned incentives in medical care. He has extended the same value-based treatment philosophy to the island of Puerto Rico through OA’s wholly owned subsidiary Soluciones Analiticas de Salud (SAS), which provides preauthorization review of oncology treatments to local health plans.
Balbino Vazquez, CFO
Chief Financial Officer
Mr. Balbino Vazquez serves as the Chief Financial Officer of Oncology Analytics, Inc. Mr. Vazquez joined Oncology Analytics in 2011. He served as Senior Vice President of Long Term Care at Independent Living Systems, LLC from February 2012 to July 2015. In this capacity, Mr. Vazquez was responsible for all managed long term care project implementations, clinical and market operations for ILS. Prior to joining ILS, he was with Humana Medical Plan, Inc. for the prior 25 years in various capacities.
In his last two assignments, he served as Vice-President and Chief Financial Officer for the Florida market operations from 2001 to 2011 overseeing $5 billion in annual revenues, and from 1995 to 2001 he was Associate Executive Director of Provider Systems overseeing Humana’s capitated and risk contract reimbursement systems and operations. Originally from Spain, Balbino is bilingual, and works closely overseeing reporting and analytics to OA in the U.S., and to SAS clients in Puerto Rico. He is a graduate of the University of Miami in 1986.
oncology-analytics-richard-wilderRichard Wilder, MD, MBA
Chief Medical Officer
Dr. Wilder graduated from the University of Maryland School of Medicine. He completed an internal medicine internship at the Greater Baltimore Medical Center, a radiation oncology residency at the University of Arizona, and an ASTRO research fellowship at the Stanford University Medical Center. He subsequently worked as a radiation oncology faculty member at UCSF, as well as the MD Anderson Cancer Center. Later, he obtained an MBA from Johns Hopkins University.
Recently, Dr. Wilder served for 2 1/2 years as interim chair of the Department of Radiation Oncology at the Moffitt Cancer Center. During this time, he worked on radiation oncology treatment guidelines. Also, he served for five years as a Kidney and Testicular Cancer Panel Member for the NCCN, helping to write national evidence-based treatment guidelines. In addition, since 2002 he has served nationally as an oral board examiner for the American Board of Radiology. Dr. Wilder joined Oncology Analytics in 2016 as its Chief Medical Officer.
oncology-analytics-dr-bolgerGraeme B. Bolger, MD
Medical Director
Dr. Bolger is a Medical Director of Oncology Analytics. He is board-certified in Medical Oncology and Internal Medicine. Dr. Bolger is a MD graduate of McGill University, Montreal, Canada. He completed his residency in Internal Medicine at The Johns Hopkins Hospital in Baltimore, MD, and a fellowship in Medical Oncology at Memorial Sloan-Kettering Cancer Center, New York, NY, and Fred Hutchinson Cancer Research Center, Seattle, WA.
Prior to joining Oncology Analytics, Dr. Bolger had 21 years of experience in academic medicine, as an assistant professor at the University of Utah Health Sciences Center and an Associate Professor at the University of Alabama, Birmingham, AL. He has published over 65 full-length research papers in peer-reviewed journals. He was a member of the NCCN guidelines panels in testis and kidney cancer for over six years.